http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

Note - Streaming News is only available to subscribers to the Active Level and above



Summit Corporation PLC : Initiation of Phase 1 ...
HUG
Summit Corporation plc
('Summit' or 'the Company')

SUMMIT ANNOUNCE INITIATION OF PHASE 1 CLINICAL TRIAL OF SELECTIVE ORAL ANTIBIOTIC FOR THE TREATMENT OF C. DIFFICILE INFECTION

Oxford, UK, 31 October 2012 - Summit (AIM: SUMM), a UK drug discovery company, announces that it has initiated dosing of healthy volunteers in the Phase 1 clinical trial of SMT 19969, the novel, oral small molecule being developed as a selective antibiotic for the treatment of infections caused by the bacteria C. difficile. The trial is being supported as part of a £4.0m Translation Award from the Wellcome Trust.

"C. difficile infection remains a serious illness in hospitals, long-term care homes and increasingly the wider community, and current treatment options remain limited," commented Glyn Edwards, Chief Executive Officer of Summit. "Our novel antibiotic SMT 19969 is a selective treatment of C. difficile infection and we are very excited about advancing this promising drug into human clinical trials."

The Phase 1 trial is a randomised, dose-escalating, placebo-controlled study that will evaluate the safety, tolerability and pharmacokinetics of SMT 19969. The study will enrol 56 healthy volunteers who will be divided into several cohorts and will receive single ascending doses and multiple ascending doses of SMT 19969. Headline results from the Phase 1 trial are expected to be reported in H1 2013.

Notes to Editors

About C. difficile Infection
C. difficile infection ('CDI') is a serious healthcare threat in hospitals, long-term care homes and increasingly the wider community. It is a serious illness that is caused by infection of the colon by the bacteria C. difficile, which produces toxins that cause inflammation, severe diarrhoea and in the most serious cases can be fatal. Patients typically develop CDI following the use of broad-spectrum antibiotics that disrupt the normal gastrointestinal (gut) flora and so allow the C. difficile bacteria to flourish. Existing CDI antibiotics cause further damage to the gut flora and are associated with recurrent disease. This is the key clinical issue as repeat episodes are typically more severe and associated with an increase in mortality rates and healthcare costs.

About SMT 19969
SMT 19969 is a novel, oral small molecule antibiotic that is being specifically developed for the treatment of CDI. Results from non-clinical efficacy studies show that SMT 19969 combines potent activity against C. difficile with exceptionally high levels of antibacterial selectivity. This narrow spectrum antibiotic has displayed efficacy in two key disease models while showing complete protection against recurrent disease. SMT 19969 is targeted to the GI tract, the site of infection, and has exceptionally low levels of resistance development coupled with an excellent safety profile.

About Summit
Summit is an Oxford, UK based drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).

About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. www.wellcome.ac.uk

- END -

For more information, please contact:

Summit Corporation PLC : Repeat Dosing of SMT C...
HUG
Summit Corporation plc
('Summit' or 'the Company')

REPEAT DOSING OF SMT C1100 FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY MEETS ENDPOINTS IN PHASE 1 CLINICAL TRIAL

New formulation delivers drug levels that are predicted to significantly increase utrophin production

Summit to progress utrophin upregulator into next stages of development

Oxford, UK, 7 November 2012 - Summit (AIM: SUMM), a UK drug discovery company, announces that the repeat dosing of the utrophin upregulator SMT C1100 for the treatment of the fatal muscle-wasting disease Duchenne Muscular Dystrophy ('DMD') has successfully met the endpoints as part of a Phase 1 clinical trial in healthy volunteers. The trial evaluated a new formulation of SMT C1100 and the results showed that upon repeat dosing, concentrations of the drug achieved in the blood plasma, stabilised at levels that from preclinical studies are expected to significantly increase utrophin protein production. The new formulation was also shown to be safe and well-tolerated in this Phase 1 trial.

SMT C1100 is a potential disease-modifying, oral small-molecule that works by upregulating (increasing) the amount of a naturally occurring protein called utrophin to maintain the healthy function of muscles. These data strongly support the progression of SMT C1100 into the next stages of development that includes biomarker and long-term safety studies, which will be required before a DMD patient efficacy trial could commence. The latest results will be presented at the 2012 Action Duchenne Conference, 9-10 November, London UK.

"Utrophin upregulation is a unique approach for treating DMD because it could benefit all DMD patients, regardless of their underlying genetic fault," commented Glyn Edwards, Chief Executive Officer of Summit. "We are highly encouraged by these results, as the new formulation achieves blood concentrations that have the potential to significantly increase utrophin levels, with the outcome of maintaining the healthy function of muscles in patients with DMD. The results therefore strongly support continuing clinical evaluation of SMT C1100."

The double blind, placebo-controlled Phase 1 trial examined a new nanoparticle aqueous suspension of SMT C1100 in a total of 48 healthy volunteers. The previously reported results from the single ascending dose cohort showed SMT C1100 to be safe and well-tolerated at all doses. These new data are being reported from the repeat dosing cohort where the volunteers received 100mg/kg twice daily for nine days. These results show that in all volunteers the blood plasma concentration of SMT C1100 stabilised after four days of dosing above the required level expected to increase utrophin protein production by 50% for at least 14 hours a day in a preclinical model. The plasma levels achieved were equivalent to those that gave significant therapeutic benefit in the gold standard disease model of DMD.

A copy of the presentation being given at the Action Duchenne conference will be available on Summit's website after the event.

The Phase 1 trial has received funding from a group of US DMD foundations: the Muscular Dystrophy Association, Charley's Fund, Cure Duchenne, the Foundation to Eradicate Duchenne, Nash Avery Foundation and Parent Project Muscular Dystrophy.

About SMT C1100 & Utrophin Upregulation
SMT C1100 is designed to upregulate and maintain the production of utrophin. Utrophin is a protein that is highly expressed in foetal and regenerating muscle but decreases as the muscle fibre mature and is eventually replaced by dystrophin, a similar protein that maintains the integrity and healthy function of muscles. Patients with DMD are unable to make dystrophin, resulting in muscle fibre degeneration. However, if utrophin is continually expressed in the mature fibre, it can functionally replace dystrophin and is expected to overcome the deficit in patients with DMD. This approach is expected to be a universal treatment for all DMD patients regardless of whether the disease was caused by an inherited or spontaneous mutation. Summit has demonstrated in non-clinical efficacy studies that SMT C1100 is capable of switching utrophin production back-on to restore and maintain the healthy function of muscles including the heart and diaphragm. SMT C1100 has been granted orphan drug status in Europe and the US.

About Summit
Summit is an Oxford, UK based drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).

Good day for summit up 10%

Summit shares surge following latest, highly encouraging update on DMD drug study
12:15 pm by Ian LyallThe initial market reaction was muted, though in the latter part of the morning a spike in buying activity sent the share price 0.65 pence higher to 5.65 pence.

Shares in Summit (LON:SUMM) rose 13 per cent after the drug developer unveiled highly encouraging results from the repeat dosing of its SMT C1100 treatment for Duchenne Muscular Dystrophy.

The phase I trial, which supports C1100’s transition into the next phase of clinical studies, revealed that concentrations of the drug were detected at levels that expected to significantly increase utrophin protein production.

This is important on two levels. First the group hopes to use utrophin to compensate for the lack of dystrophin that is at the root of DMD.

It also potentially offers a means to treat all suffers of this fatal, but thankfully rare condition that only affects boys.

DMD is caused by mutations in the dystrophin gene. This gene contains the instructions for making dystrophin protein, which acts as a shock absorber to prevent damage when muscles contract.

It is thought that utrophin, a protein naturally present in the body in small amounts, may be able to make up for the lack of dystrophin in boys with DMD since both proteins are structurally similar and appear to have very similar functions.

“Utrophin upregulation is a unique approach for treating DMD because it could benefit all DMD patients, regardless of their underlying genetic fault,” said Glyn Edwards, chief executive of Summit.

“We are highly encouraged by these results, as the new formulation achieves blood concentrations that have the potential to significantly increase utrophin levels, with the outcome of maintaining the healthy function of muscles in patients with DMD.

“The results therefore strongly support continuing clinical evaluation of SMT C1100. The company said the latest data strongly support the drug’s transition into the next phase of clinical studies.”

The initial market reaction was muted, though in the latter part of the morning a spike in buying activity sent the share price 0.65 pence higher to 5.65 pence.

The stock has more than doubled in value since the start of September.

N+1 Singer was encouraged by the latest update from the company. Analyst Sheena Berry said: “The data provides strong support for the further development of C1100 as a novel treatment for DMD, a fatal muscle wasting disease with no current cure.

“Unlike other approaches in development, C1100 can potentially by used to treat 100 per cent of boys with DMD and in combination with other agents.”

The news has come thick and fast in the past six weeks for Summit, which has enjoyed clinical success as well as sealing deals with drugs giant Bristol-Myers Squibb and the Wellcome Trust charity.

Meanwhile, last week it revealed it begun the dosing stage of a phase 1 clinical trial of a potential antibiotic treatment for C.Difficile infections.

Yep, nice one!

Summit CEO "really excited" about prospects, but share price "woefully low"
Friday, November 09, 2012

http://www.proactiveinvestors.co.uk/companies/stocktube/1434/summit-ceo-really-excited-about-prospects-but-share-price-woefully-low-1434.html

up 8%

Proactive Investors One2One Investor Forum

22 November 2012, London UK

Summit Corporation PLC : Summit Appoints Mr Jim...
HUG
Summit Corporation plc
('Summit' or 'the Company')

SUMMIT APPOINTS MR JIM MELLON AND DR FRANK ARMSTRONG AS NON-EXECUTIVE DIRECTORS

Oxford, UK, 22 November 2012 - Summit (AIM: SUMM), a UK drug discovery and development company, is pleased to announce that it has appointed Mr Jim Mellon and Dr Frank Armstrong as Non-Executive Directors. The addition of Mr Mellon and Dr Armstrong to Summit's Board of Directors is part of the Company's previously announced strategic shift to focus on its clinical-stage programmes for the treatment Duchenne Muscular Dystrophy (DMD) and C. difficile infections.

Mr Jim Mellon is a renowned investor and entrepreneur with interests in several industries. Jim is an active investor in the biopharmaceutical industry and is a Non-Executive Director of the UK biotechnology company, Plethora Solutions plc and of the biopharmaceutical investment company, Port Erin BioPharma plc.

Dr Frank Armstrong is an experienced, medically qualified Pharmaceutical Executive who has worked at Board level at a number of companies in the UK, US, Switzerland and Germany. He has extensive experience of all aspects of medical and product development in large and small companies and has led successful product approvals in the US and Europe across a range of therapeutic areas.

"Jim and Frank will bring considerable business, clinical and product development expertise to support the future growth of Summit," commented Dr Barry Price, Chairman of Summit. "We welcome them and look forward to their contributions and strategic guidance as we focus on advancing our high-value clinical programmes targeting Duchenne Muscular Dystrophy and C. difficile infections."

With the appointment of the new directors, Dr Richard Storer, Dr Andy Richards and Mr George Elliott will be stepping down from the Board effective immediately.

Dr Price continued, "On behalf of the Board, I would sincerely like to thank Dick, Andy and George for their contribution towards the development of Summit over many years. In a challenging environment, their efforts have been invaluable in establishing a firm foundation that the Board believes will support the future growth of the business and we wish them every success for the future."

About Jim Mellon
Mr. Jim Mellon (55) began his career in the United States and Hong Kong with GT Management and later Thornton Management (Asia) Limited. Jim co-founded Regent Pacific Group, Ltd and Charlemagne Capital Limited. He is currently Executive Chairman of Manx Financial Group plc and Speymill plc, Non-Executive Co-Chairman of Regent Pacific Group Ltd and West Africa Minerals Corporation and Non-Executive Chairman of Speymill Deutsch Immobilien Company plc. In addition, he is a Non-Executive Director of Charlemagne Capital Limited, Condor Resources plc, Polo Resources Limited and various other investment companies. He is also the Chairman of the private asset manager, the Burnbrae Group Limited.

Jim has also written a number of investment books including his latest publication about the biotechnology industry titled "Cracking the Code" and he is a graduate of Oxford University.

Galloway Limited, a company wholly owned by a trust of which Jim Mellon is a life tenant, has a beneficial interest in 25,000,001 Ordinary shares of the Company that represents approximately 7.1% of the issued share capital. No further disclosures are required under Rule 17 and Schedule 2(g) of the AIM Rules.

About Frank Armstrong
Dr. Frank Armstrong (55) has held Chief Executive roles with five biotechnology companies (public and private) one of which was Fulcrum Pharma, an AIM-listed Professional Services Company that was sold to Private Equity Investors in 2009. In 2007 he led the sale of 454 Life Sciences from CuraGen to Roche. Most recently, Frank led Medical Research and Innovation (MSI) at Merck Serono and previously was Head of Worldwide Product Development at Bayer and Senior Vice President of Medical Research and Communications Group at Zeneca.

With experience as a Non-Executive Director in the UK and US working with private and NASDAQ listed companies and as Chairman of a Charitable Institution, Frank has moved successfully between large and small companies during his career.

Dr Armstrong is currently Chairman of Xceleron Inc., Executive Chairman of Asceneuron, Non-Executive Director of Actino Pharma and a Member of the Scientific Advisory Board of Healthcare Royalty Partners. Dr Armstrong is a Fellow of the Royal College of Physicians. There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules.

UPDATE: Summit appoints Mellon and Armstrong to the board
11:37 am by Ian LyallThe two new appointments strengthen the board's business and industry ties.



---ADDS PRICE TARGET, BROKER COMMENT---

Drug discovery group Summit (LON:SUMM) said the entrepreneur and investor Jim Mellon is one of two new non-executive directors that have been appointed to the board.

The other is Frank Armstrong, a medically qualified doctor who has worked at board level on a number of pharmaceutical companies.

“Jim and Frank will bring considerable business, clinical and product development expertise to support the future growth of Summit,” said Summit chairman Dr Barry Price

“We welcome them and look forward to their contributions and strategic guidance as we focus on advancing our high-value clinical programmes targeting Duchenne Muscular Dystrophy [DMD] and C. difficile infections.”

Today’s is the latest in a flurry of announcements that are slowly changing the face of Summit.

It is successfully developing its two key treatments – for DMD and C.diff - and has forged impressive links with big pharma, as well as uncovering innovative and dilutive sources of funding.

Its progress is reflected in a share price that has almost doubled in value since September 10.

The shares, which have more than doubled in value in the last two months, rose 3% to 4.9 pence on the news.

However broker N+1 Singer reckons Summit “intrinsic value” is 13.3 pence a share.

Talking about today’s news, analyst Sheena Berry said: “We believe the appointment of Mellon and Armstrong supports the group’s change in focus and strengthens its position to progress the two programmes through clinical trials.

“We continue to believe that Summit is a high quality business in a strong position to penetrate its target markets, particularly given the recent stream of positive news flow regarding clinical trial progression.”

Company Presentation
22 November 2012

http://www.summitplc.com/userfiles/file/201211_Corporate%20presentation_Proactive%20Forum%20FINAL.pdf

:-))

I bought in @3.5p back in April...so I'm happy with the way it's going...onwards & upwards! QPP going well for me as well!

Well done Sh.

Summit Corporation PLC : Award of Share Options
HUG
Summit Corporation plc
('Summit' or 'the Company')

AWARD OF SHARE OPTIONS

Oxford, UK, 27 December 2012 - Summit (AIM: SUMM), a UK drug discovery and development company, today announces that on 24 December 2012 it granted Share Options over 10,000,000 shares to certain individuals at an exercise price of 4.25 pence per share. The options will vest subject to achieving certain performance conditions.

This share option award is part of Summit's strategic shift to focus on the development of its clinical-stage programmes for the treatment of Duchenne Muscular Dystrophy ('DMD') and Clostridium difficile infections ('CDI') and will help motivate and retain personnel who are key to the success of the respective programmes. The Board believes this award is aligned with the interests of all shareholders as the Company seeks to generate shareholder value.

The options will fully vest on the third anniversary of date of grant subject to achieving the performance condition of the average closing share price being equal to or greater than 8.0 pence in any period of 30 consecutive calendar days ending on or before the third anniversary. The options will lapse if the performance condition is not met by the third anniversary of date of grant.

The total number of options being awarded represents 2.8% of the Company's current issued share capital. There are no options being awarded to Executive Directors or Officers at this time.

Notes to Editors

About Summit
Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.

- END -

Summit Corporation plc
('Summit' or 'the Company')

SUMMIT AND CHILDREN'S NATIONAL MEDICAL CENTER ENTER UTROPHIN BIOMARKER COLLABORATION FOR DUCHENNE MUSCULAR DYSTROPHY

•
Collaboration Supported by Grant from Foundation to Eradicate Duchenne


Oxford, UK, 6 February 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infections, announces that it has entered into a collaboration with Dr Yetrib Hathout from Children's National Medical Center in Washington DC, for the development of utrophin biomarkers for DMD. The collaboration is being financially supported by a grant from the Foundation to Eradicate Duchenne and is part of a comprehensive biomarker programme being undertaken by Summit to advance its utrophin modulator programme for DMD. In late 2012, Summit reported that in a Phase 1 trial in healthy volunteers, its lead candidate SMT C1100 was safe and well-tolerated.

"We are delighted to be working with Dr Hathout on developing new biomarkers that will help advance our understanding of DMD while supporting the progress of Summit's utrophin modulator programme," commented Glyn Edwards, Chief Executive Officer of Summit. "Developing biomarker indicators capable of accurately measuring utrophin protein levels in muscle will be vital in helping to confirm the activity of our clinical candidate SMT C1100 in future patient trials. We thank the Foundation to Eradicate Duchenne for their continuing support in advancing this important medical research."

Joel Wood, President of the Foundation to Eradicate Duchenne added, "We are committed to ensuring that urgently needed treatments have the best possible chance of successfully progressing through clinical trials. As such, we are pleased to provide funding to support Summit's utrophin modulation programme, which is a novel and promising approach for treating all genetic forms of DMD."

DMD is caused by genetic mutations that prevent patients from making the structural protein dystrophin, which leads to progressive muscle wasting and is ultimately fatal. Summit is pioneering utrophin modulation to stimulate production of utrophin, a functionally similar protein to dystrophin that is expressed in foetal and regenerating muscle, and which has the potential to restore and maintain healthy muscle function. This disease modifying approach would benefit all DMD patients, regardless of the underlying genetic fault causing their illness. SMT C1100 is the Company's leading utrophin modulator drug and successfully completed a Phase 1 clinical trial in late 2012.

The development of new biomarkers that accurately quantify utrophin protein levels in DMD muscles will play an important role in providing evidence for the potential effectiveness of Summit's utrophin modulator drugs in future patient clinical trials. Dr Hathout, a Principal Investigator at the Center for Genetic Medicine Research at Children's National, will apply his expertise in cutting-edge proteomic techniques to develop a sensitive, robust mass-spectrometry based assay that can quantitatively measure utrophin protein levels in biopsies of DMD muscle. This collaboration is part of Summit's comprehensive biomarker programme developing a range of assays that will measure biological endpoints to demonstrate muscle benefit after treatment with small molecule utrophin modulators

UPDATE: Summit teams up with Children's National Medical Center
1:30 pm by John Harrington This collaboration is part of Summit's comprehensive biomarker programme developing a range of assays that will measure biological endpoints to demonstrate muscle benefit after treatment with small molecule utrophin modulators.

-- Adds comments from chief executive and broker --

Summit (LON:SUMM) has received a boost to its Duchenne Muscular Dystrophy (DMD) project with a charitable foundation agreeing to fund part of its testing programme.

The company is teaming up with the highly respected Dr Yetrib Hathout from Children's National Medical Center in Washington DC to develop utrophin biomarkers for DMD.

The collaboration is being financially supported by a grant from the Foundation to Eradicate Duchenne and is part of a comprehensive biomarker programme being undertaken by Summit to advance its utrophin modulator programme for DMD.

Utrophin is a protein that exists in muscle cells, and Summit already has a drug in development – SMT C1100 – which is designed to increase utrophin production as a treatment for DMD.

In a Phase 1 trial in healthy volunteers last year, SMT C1100 was deemed safe and well-tolerated.

“Developing biomarker indicators capable of accurately measuring utrophin protein levels in muscle will be vital in helping to confirm the activity of our clinical candidate SMT C1100 in future patient trials," said Glyn Edwards, chief executive officer of Summit.

Speaking to Proactive Investors, Edwards said that since the company refocused last year on just two programmes – the DMD drug SMT C1100 and the C. difficile infection treatment SMT 19969 – progress has come on in “leaps and bounds”.

“One of the big next steps is to do a trial … to find out whether the drug works or not … but that covers a multitude of sins. You’ve got to have ways of measuring how effective the drug is, and because this is a new approach to the treatment for a disease that has got no cures at the moment, then the measurement side is having to be developed as well as the drug side,” Edwards explained.

For that you need biomarkers: biological molecules found in blood, other body fluids, or tissues that provide a sign of a normal or abnormal process, or the activity of a disease.

Edwards said that developing biomarkers is “the hot thing” in the pharmaceutical industry as they can be used to see how well the body responds to a treatment for a disease, but, unfortunately, no company has developed a new biomarker for DMD that Summit can piggy-back on.

Consequently, the company has to work with leading academics, such as Dr Hathout, who is a Principal Investigator at the Center for Genetic Medicine Research at Children's National. He will apply his expertise in proteomic techniques to develop a sensitive, robust mass-spectrometry based assay that can quantitatively measure utrophin protein levels in biopsies of DMD muscle.

Edwards said the company is delighted to be working with Dr Hathout, and with the collaboration being wholly financed by the US organisation, the Foundation to Eradicate Duchenne, today’s deal is a “win-win for everyone”.

DMD is caused by genetic mutations that prevent patients from making the structural protein dystrophin, which leads to progressive muscle wasting. Except in very few circumstances, the disease only affects boys.

Fortunately, the number of people suffering from the disease is relatively small – Edwards said there are known to be about 50,000 sufferers scattered across North America, Europe and Japan – but the price for an effective treatment that can extend and improve the quality of a patient’s life is potentially high.

“Keeping the maths simple, let’s say the cost of treatment is $100,000 a year. With 50,000 sufferers that’s a potential $5bn a year market opportunity,” Edwards noted.

That explains why Summit chose to focus on developing a treatment.

Summit is pioneering utrophin modulation to stimulate production of utrophin, a functionally similar protein to dystrophin that is expressed in foetal and regenerating muscle, and which has the potential to restore and maintain healthy muscle function. This disease modifying approach would benefit all DMD patients, regardless of the underlying genetic fault causing their illness, Summit says.

This collaboration is part of Summit's comprehensive biomarker programme developing a range of assays that will measure biological endpoints to demonstrate muscle benefit after treatment with small molecule utrophin modulators.

Edwards said the company is hopeful other charities will chip in to help with other aspects of the biomarker programme.

In a research note, Sheena Berry and Jens Lindqvist of broker N+1 Singer said: “This agreement is in line with the company’s plans for the further development of SMT C1100 as a novel treatment for DMD, a fatal muscle wasting disease with no current cure. Unlike other approaches in development, SMT C1100 can potentially by used by 100% of boys with DMD and in combination with other agents. We re-iterate a positive stance and 13.3p price target.”

Summit shares currently trade at 4.5p.

Summit Corporation PLC : Research Update
HUG
Summit Corporation plc
('Summit' or 'the Company')

SUMMIT FORMS ADVISORY BOARD TO SUPPORT DEVELOPMENT OF DUCHENNE MUSCULAR DYSTROPHY PROGRAMME

Oxford, UK, 13 February 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infections, announces the formation of an Advisory Board ('the Board') to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease DMD. The Board brings together six world-renowned scientists and clinicians with expertise in the field of neuromuscular diseases, and particularly DMD.

"We are absolutely delighted to have brought together these eminent thought leaders in neuromuscular diseases to form a world-class Advisory Board that will support our DMD programme," commented Glyn Edwards, Chief Executive Officer of Summit. "Their expertise brings a deep insight into the disease and will provide invaluable input into future patient clinical trials to support the progression of our utrophin modulation programme, including our lead candidate SMT C1100."

"Summit's utrophin modulation program is a very promising approach that offers the opportunity to treat all the genetic forms of DMD," added Dr Kenneth Fischbeck, NIH Distinguished Investigator and member of the Advisory Board. "I look forward to working with this outstanding group of clinicians and scientists, and contributing to the progress of Summit's DMD program as we explore the potential of utrophin modulation as an effective treatment for this disease."

The members of Summit's DMD Advisory Board are:

Kate Bushby, MD, Professor of Neuromuscular Genetics at Newcastle University, Deputy Director of MRC Centre for Neuromuscular Diseases at London and Newcastle. Professor Bushby, a clinical academic at one of the leading international neuromuscular centres, is involved in an extensive programme of research in neuromuscular diseases from basic molecular pathology to clinical studies. Professor Bushby is one of the founding coordinators of the TREAT-NMD network and is a member of the Scientific Advisory Committees of the French Muscular Dystrophy Association ('AFM'), Action Duchenne and Parent Project Muscular Dystrophy.

Kay E Davies, MA, DPhil, DBE, FMedSci, FRS, Dr Lee's Professor of Anatomy, Director MRC Functional Genomics Unit, and Associate Head of the Medical Sciences Division at the University of Oxford. Professor Davies has a long-standing research interest in neuromuscular diseases and is a pioneer of utrophin modulation as a therapeutic approach for the treatment of DMD. Professor Davies is Chair of Action Duchenne's Scientific Advisory Board, a member of the Science Committee of the Muscular Dystrophy Campaign and a Governor of the Wellcome Trust.

Kenneth H Fischbeck, MD, NIH Distinguished Investigator and Chief of the Neurogenetics Branch at National Institute of Neurological Disorders and Stroke ('NINDS'). Dr Fischbeck's research focuses on identifying the causes and mechanisms of hereditary neurological and neuromuscular diseases with a particular interest in muscular dystrophy. Dr Fischbeck serves on advisory boards for the Muscular Dystrophy Association and the French Muscular Dystrophy Association ('AFM').

Louis M Kunkel, PhD, Professor of Pediatrics and Genetics at Harvard Medical School, and Director of Program in Genomics at Boston Children's Hospital. Professor Kunkel is an internationally recognised geneticist whose research identified the gene and encoded protein dystrophin that is mutated in boys with DMD. Professor Kunkel has a longstanding interest in developing therapies for the muscular dystrophies. Professor Kunkel is Chairman of the Muscular Dystrophy Association's Scientific Advisory Committee.

Francesco Muntoni, MD, PhD, Chair of Paediatric Neurology at the Institute of Child Health, London, and Director of the Dubowitz Neuromuscular Centre at University College London. Professor Muntoni is a paediatric neurologist at the UK's largest paediatric neuromuscular centre of excellence and has a long standing interest in the clinical and molecular aspects of neuromuscular diseases including DMD. Professor Muntoni is a member of the Scientific Advisory Committee of the Italian Telethon and Chair of the Scientific Advisory Board of the Myotubular Trust.

H Lee Sweeney, PhD, William Maul Massey Professor, Chairman of Physiology, and Director of the Center for Orphan Disease Research and Therapy at the University of Pennsylvania's Perelman School of Medicine. Dr Sweeney is a physiologist whose research interests evaluate the possible causes and treatments of muscle diseases, with a particular focus on DMD. Dr Sweeney is the Senior Scientific Advisor to the Parent Project Muscular Dystrophy.

- END -

Summit Corporation PLC : New Data Reported from...
HUG
Summit Corporation plc
('Summit' or 'the Company')

NEW DATA REPORTED FROM PRECLINICAL EFFICACY STUDY OF OGA INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED TAUOPATHIES

Improvement in symptoms of motor impairment, increased survival recorded

New data presented at International conference on dementia

Oxford, UK, 11 March 2013 - Summit (AIM: SUMM), a drug discovery and development company, reports new data from its OGA (O-linked N-acetylglucosaminidase) inhibitor programme for the treatment of tauopathies, a group of neurodegenerative diseases that includes Alzheimer's disease. The OGA inhibitors were evaluated in an in vivo disease model, with results showing trends to a positive impact on motor impairment symptoms and improved survival rates following daily oral dosing. These new data were presented at AD/PD(TM) 2013, the international conference on Alzheimer's and Parkinson's diseases held in Florence, Italy, 6-10 March.

"Following the strategic refocusing of Summit to commit all resources into advancing our two clinical-stage programmes, the completion of this study represents the natural conclusion of our involvement in this programme," commented Glyn Edwards, Chief Executive Officer of Summit. "The inhibition of the enzyme OGA has emerged as a potential new treatment paradigm for Alzheimer's disease and related tauopathies. These encouraging results further highlight the promise of the approach and of our OGA inhibitors, and will add greater depth to the scientific data package as we talk with perspective collaborators about taking this programme further into development."

Summary of Results from Preclinical Efficacy Study
The study evaluated the OGA inhibitors, previously identified using Seglin(TM) technology, in a transgenic tauopathy disease model to determine the effect that prolonged dosing had on motor impairments related to the disease and survival rates. The tauopathies are also characterised by reduced levels of O-GlcNAcylated tau protein and raised levels of hyper-phosphorylated tau protein. In summary, the results of daily oral dosing with the Seglin inhibitors for 10 weeks were:

A clear trend for reduced clasping, a clinical sign indicative of motor impairment, and improved survival rates compared to the untreated cohort;

A statistically significant increase in O-GlcNAcylated protein levels in the brain with the increased global levels maintained on repeat dosing to demonstrate that the OGA inhibitor accessed the brain compartment at therapeutically relevant concentrations;

No observed change in tau protein phosphorylation levels although this is consistent with precedent from the scientific literature;

No associated toxicity or adverse effects from prolonged dosing observed.

The full results were reported at AD/PD(TM) 2013 held in Florence, Italy, 6-10 March 2013, and a copy of the presentation is available from www.summitplc.com.

Summit reveals encouraging early data for potential Alzheimer’s treatment
7:29 am by Ian LyallThe new data were presented at an Alzheimer's and Parkinson's diseases conference in Florence that ended yesterday.

Drug developer Summit (LON:SUMM) has unveiled encouraging new data on its OGA inhibitor emanating from a pre-clinical study of efficacy in Alzheimer’s and related diseases.

The inhibition of OGA, or O-linked N-acetylglucosaminidase, has emerged as a potential method of treating tauopathies, a group of neurodegenerative diseases that includes Alzheimer's.

The in-vivo (in animal) disease model pointed to a positive impact on motor impairment symptoms and improved survival rates following daily oral dosing.

These new data were presented at an Alzheimer's and Parkinson's diseases conference in Florence that ended yesterday.

The company’s focus on its two lead drug candidates – one for Duchenne Muscular Dystrophy, the other for c.difficile infection – means the group will look for a partner to take research further.

"Following the strategic refocusing of Summit to commit all resources into advancing our two clinical-stage programmes, the completion of this study represents the natural conclusion of our involvement in this programme," said Summit chief executive Glyn Edwards.

"The inhibition of the enzyme OGA has emerged as a potential new treatment paradigm for Alzheimer's disease and related tauopathies. “These encouraging results further highlight the promise of the approach and of our OGA inhibitors, and will add greater depth to the scientific data package as we talk with prospective collaborators about taking this programme further into development